Table of Content

Chapter 1. Executive Summary: Cancer Gene Therapy Market
Chapter 2. Research Methodology & Research Framework

2.1. Research Objective
2.2. Therapy Overview
2.3. Market Segmentation
2.4. Qualitative Research
2.4.1. Primary & Secondary Sources
2.5. Quantitative Research
2.5.1. Primary & Secondary Sources
2.6. Breakdown of Primary Research Respondents, By Region
2.7. Assumption for Study
2.8. Market Size Estimation
2.9. Data Triangulation

Chapter 3. Cancer Gene Therapy Market Overview

3.1. Industry Value Chain Analysis
3.1.1. End-User Provider
3.1.2. Manufacturer
3.1.3. Distributor
3.1.4. End-Users
3.2. Industry Outlook
3.2.1. Overview of Cancer Gene Therapy Market
3.2.2. EXIM Data
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitutes
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Dynamics and Trends
3.5.1. Growth Drivers
3.5.1.1. Increasing Regulatory Approvals for Gene Therapy Products, Accelerating Cancer Treatment Innovation and Patient Access
3.5.2. Restraints
3.5.2.1. High Cost of Treatment
3.5.3. Opportunity
3.5.3.1 Development of Novel Non-Viral Vectors for Gene Delivery Enhancing Safety and Efficacy in Cancer Therapy
3.5.4. Key Trend
3.6. Market Growth and Outlook
3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2025 – 2035
3.6.2. Price Trend Analysis

Chapter 4. Competition Dashboard

4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2025
4.3. Competitor Mapping & Benchmarking

Chapter 5. Cancer Gene Therapy Market Analysis

5.1. Key Insights
5.2. Market Size and Forecast, 2026-2035 (US$ Mn)
5.2.1. By Therapy
5.2.1.1. Gene Induced Immunotherapy
5.2.1.2. Gene Transfer
5.2.1.3. Oncolytic Virotherapy
5.2.2. By End-User
5.2.2.1. Biopharmaceutical Companies
5.2.2.2. Diagnostic centers
5.2.2.3. Hospitals
5.2.2.4. Research Institutes
5.2.2.5. Others
5.2.3. By Region
5.2.3.1. North America
5.2.3.1.1. The U.S.
5.2.3.1.2. Canada
5.2.3.1.3. Mexico
5.2.3.2. Europe
5.2.3.2.1. Western Europe
5.2.3.2.1.1. UK
5.2.3.2.1.2. Germany
5.2.3.2.1.3. France
5.2.3.2.1.4. Italy
5.2.3.2.1.5. Spain
5.2.3.2.1.6. Rest of Western Europe
5.2.3.2.2. Eastern Europe
5.2.3.2.2.1. Poland
5.2.3.2.2.2. Russia
5.2.3.2.2.3. Rest of Eastern Europe
5.2.3.3. Asia Pacific
5.2.3.3.1. China
5.2.3.3.2. India
5.2.3.3.3. Japan
5.2.3.3.4. South Korea
5.2.3.3.5. Australia & New Zealand
5.2.3.3.6. ASEAN
5.2.3.3.7. Rest of Asia Pacific
5.2.3.4. Middle East & Africa
5.2.3.4.1. UAE
5.2.3.4.2. Saudi Arabia
5.2.3.4.3. South Africa
5.2.3.4.4. Rest of MEA
5.2.3.5. South America
5.2.3.5.1. Argentina
5.2.3.5.2. Brazil
5.2.3.5.3. Rest of South America

Chapter 6. North America Cancer Gene Therapy Market Analysis

6.1. Market Dynamics and Trends
6.1.1. Growth Drivers
6.1.2. Restraints
6.1.3. Opportunity
6.1.4. Key Trends
6.2. Market Size and Forecast, 2026-2035 (US$ Mn)
6.2.1. By Therapy
6.2.2. By End-User
6.2.3. By Region

Chapter 7. Europe Cancer Gene Therapy Market Analysis

7.1. Market Dynamics and Trends
7.1.1. Growth Drivers
7.1.2. Restraints
7.1.3. Opportunity
7.1.4. Key Trends
7.2. Market Size and Forecast, 2026-2035 (US$ Mn)
7.2.1. By Therapy
7.2.2. By End-User
7.2.3. By Region

Chapter 8. Asia Pacific Cancer Gene Therapy Market Analysis

8.1. Market Dynamics and Trends
8.1.1. Growth Drivers
8.1.2. Restraints
8.1.3. Opportunity
8.1.4. Key Trends
8.2. Market Size and Forecast, 2026-2035 (US$ Mn)
8.2.1. By Therapy
8.2.2. By End-User
8.2.3. By Application
8.2.4. By Region

Chapter 9. Middle East & Africa Cancer Gene Therapy Market Analysis

9.1. Market Dynamics and Trends
9.1.1. Growth Drivers
9.1.2. Restraints
9.1.3. Opportunity
9.1.4. Key Trends
9.2. Market Size and Forecast, 2026-2035 (US$ Mn)
9.2.1. By Therapy
9.2.2. By End-User
9.2.3. By Region

Chapter 10. South America Cancer Gene Therapy Market Analysis

10.1. Market Dynamics and Trends
10.1.1. Growth Drivers
10.1.2. Restraints
10.1.3. Opportunity
10.1.4. Key Trends
10.2. Market Size and Forecast, 2026-2035 (US$ Mn)
10.2.1. By Therapy
10.2.2. By End-User
10.2.3. By Region

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Therapy landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

11.1. Abeona Therapeutics Inc.
11.2. Adaptimmune Limited
11.3. Aduro Biotech
11.4. Altor Bioscience Inc.
11.5. Asklepios BioPharmaceutical Inc.
11.6. BioCancell Inc.
11.7. Bluebird Bio Inc.
11.8. Bristol Myers
11.9. CelgeneInc
11.10. Elevate BioInc
11.11. Genelux Corporation
11.12. GenVec
11.13. GSK plc.
11.14. Introgen Therapeutics Inc
11.15. MerckKGaA
11.16. Novartis AG
11.17. OncoGenex Pharmaceuticals Inc.
11.18. Orchard Therapeutics Plc
11.19. Others

Chapter 12. Annexure

12.1. List of Secondary Sources
12.2. Macro Economic Outlook/Indicators